Information Provided By: 
Fly News Breaks for June 28, 2017
BSX
Jun 28, 2017 | 08:57 EDT
Morgan Stanley analyst David Lewis said Boston Scientific's analyst day increased his conviction the company is now a structurally faster grower than previously expected and offers a unique top to bottom profile. The analyst sees continued innovation, market share gains, and emerging market penetration and said the $2B Structural Heart and balance sheet optionality are not fully reflected in valuation. Lewis rates Boston Scientific an Overweight with a $30 price target.
News For BSX From the Last 2 Days
BSX
Apr 25, 2024 | 09:53 EDT
RBC Capital raised the firm's price target on Boston Scientific to $82 from $78 and keeps an Outperform rating on the shares. Given the company's Q1 momentum on seales and earnings, along with its new product ramp, the management's updated FY24 guidance is likely "conservative" despite easier comps, the analyst tells investors in a research note. RBC adds that the stock is its top pick in the Sector based on its "industry-leading growth profile".
BSX
Apr 25, 2024 | 08:51 EDT
BSX
Apr 25, 2024 | 08:26 EDT
BSX
Apr 25, 2024 | 08:24 EDT
Evercore ISI analyst Vijay Kumar raised the firm's price target on Boston Scientific to $78 from $72 and keeps an Outperform rating on the shares as the firm said the company reported "solid results and there wasn't much to pick on." While EP franchise acceleration driven by Farapulse PFA launch "is generally well known" by the Street, the firm says it doesn't think "anyone expected ~86% US growth and ~72% International growth."
BSX
Apr 25, 2024 | 06:59 EDT
BSX
Apr 25, 2024 | 06:47 EDT
BSX
Apr 25, 2024 | 06:37 EDT
BSX
Apr 25, 2024 | 06:29 EDT
Baird analyst David Rescott raised the firm's price target on Boston Scientific to $84 from $79 and keeps an Outperform rating on the shares. The firm noted its 1Q24 revenue/adjusted EPS beat was the biggest over the past several years and one of the most compelling in diversified LGCP MedTech.
BSX
Apr 25, 2024 | 06:22 EDT
BSX
Apr 24, 2024 | 16:20 EDT
BSX
Apr 24, 2024 | 13:53 EDT
Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.
BSX
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BSX
Apr 24, 2024 | 07:03 EDT
BSX
Apr 24, 2024 | 07:01 EDT
BSX
Apr 24, 2024 | 07:00 EDT
